Navigation Links
'Alarming' Rise Seen in Drug-Resistant Tuberculosis
Date:8/30/2012

THURSDAY, Aug. 30 (HealthDay News) -- There are alarmingly high levels of extensively drug-resistant tuberculosis in many areas of the world, a new study finds.

Researchers found high rates of resistance to at least one second-line drug (nearly 44 percent) among multidrug-resistant TB patients in eight countries in Africa, Asia, Europe and Latin America. They also found higher-than-expected overall levels of extensively drug-resistant TB.

Multidrug-resistant TB can withstand to at least two first-line drugs: soniazid and rifampicin. Extensively drug-resistant TB is resistant to isoniazid, rifampicin, a fluoroquinolone and a second-line injectable drug.

Fluoroquinolones are a class of antibiotics that include ciprofloxacin, levofloxacin and gatifloxacin.

For the study, samples collected from nearly 1,300 adults with multidrug-resistant TB in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea and Thailand were tested for resistance to 11 first-line and second-line anti-TB drugs. Overall, in nearly 44 percent of patients, resistance to any second-line drug was detected. Rates ranged from 33 percent in Thailand to 62 percent in Latvia.

Overall, one-fifth of patients had resistance to at least one second-line injectable drug, ranging from 2 percent in the Philippines to 47 percent in Latvia. The overall rate of resistance to a fluoroquinolone was nearly 13 percent, ranging from 7 percent in the Philippines to 32 percent in South Korea.

Extensively drug-resistant TB was found in 6.7 percent of patients overall, with prevalence in South Korea (15 percent) and Russia (11 percent) more than twice the current World Health Organization estimate for the same time period (5.4 percent).

The researchers also found that the risk of extensively drug-resistant TB was more than four times higher in patients previously treated for TB, and that previous treatment with second-line drugs was the strongest risk factor for resistance.

The study was published online Aug. 29 in The Lancet.

"Drug-resistant TB is more difficult and costly to treat, and more often fatal. Internationally, it is particularly worrisome in areas with fewer resources and less access to effective therapies. As more individuals are diagnosed with, and treated for, drug-resistant TB, more resistance to second-line drugs is expected to emerge," lead author Tracy Dalton, of the U.S. Centers for Disease Control and Prevention, said in a journal news release.

"So far, [extensively drug-resistant] TB has been reported in 77 countries worldwide, but exact prevalence remains unclear," Dalton noted.

"Most international recommendations for TB control have been developed for [multidrug-resistant] TB prevalence of up to around 5 percent. Yet now we face prevalence up to 10 times higher in some places, where almost half of the patients with infectious disease are transmitting [multidrug-resistant] strains," Sven Hoffner, from the Swedish Institute for Communicable Disease Control, wrote in an accompanying journal editorial.

"Updated information on [multidrug-resistant] TB and investigation of the trends are urgently needed...especially since the true scale of the burden of [multidrug-resistant] and [extensively drug-resistant tuberculosis] might be underestimated and seem to be rapidly increasing," he wrote.

More information

The U.S. Centers for Disease Control and Prevention has more about TB.

-- Robert Preidt

SOURCE: The Lancet, news release, Aug. 29, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. African Chimps Carry Drug-Resistant, Human-Linked Staph
2. Computational analysis identifies drugs to treat drug-resistant breast cancer
3. Scientists develop new strategy to overcome drug-resistant childhood cancer
4. Rare Drug-Resistant Bacteria Spotted in U.S. Hospital
5. New Medicine Might Fight Drug-Resistant TB, Study Says
6. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
7. Kinase test may yield big gains for drug-resistant cancers
8. Dartmouth medical research closes in on new tuberculosis vaccine
9. Tuberculosis increases the risk of lung cancer mortality in the elderly
10. A better tool to diagnose tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Alarming' Rise Seen in Drug-Resistant Tuberculosis 
(Date:4/27/2017)... Jacksonville, Florida (PRWEB) , ... April 27, 2017 , ... ... qualified candidates. But they will rapidly reject an outdated healthcare executive resume. , “If ... good look at your executive resume and wondering if it’s as ready as you ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... North American CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication ... 60,000 North American professional caregivers for the prestigious award each year – identifying ...
(Date:4/27/2017)... ... ... Offering the purest product of its kind, Swissx Labs AG has launched ... the market has seen before. Swissx uses proprietary strains of hemp plants grown in ... for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. Learn ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an ... it has completed a round of funding to accelerate its growth strategies. The ... Granite Capital is a growth equity firm focused on investments in healthcare and ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... DIEGO and BLOOMINGTON, Minn. ... Inc. (NASDAQ: IMMY ) ("Imprimis"), an ... Precision Lens ("Precision Lens"), today announced the signing ... the agreement, Precision Lens will deploy a dedicated ... select geographies in the U.S., primarily focused in ...
(Date:4/18/2017)... , April 18, 2017 Research and ... the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast ... ... molecular imaging equipment revenues as well as growth in the ... will provide value to market participants that design and manufacture ...
Breaking Medicine Technology: